Axsome Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | — |
| Cost of revenue | — | — | — | $5.2M | — |
| Selling, general & administrative | $570.6M | $411.4M | $323.1M | $159.3M | $66.6M |
| Research and development | $183.3M | $187.1M | $97.9M | $57.9M | $58.1M |
| Operating expenses | — | — | — | — | $124.7M |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M |
| Interest expense | $15.9M | $21.6M | $20.0M | $9.7M | — |
| Pretax income | -$183.7M | -$287.1M | -$238.3M | -$187.1M | -$130.4M |
| Income tax expense | -$530,000 | $85,000 | $960,000 | $0 | $0 |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M | -$130.4M |
| Balance Sheet | |||||
| Cash and equivalents | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M |
| Current assets | $589.0M | $485.1M | $504.3M | $245.6M | $86.5M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M |
| Current liabilities | $378.8M | $230.1M | $138.9M | $96.6M | $23.1M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M |
| Total debt | $120.0M | $180.0M | $180.0M | $95.0M | $50.0M |
| Stockholders' equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M |
| Depreciation and amortization | $503,000 | $532,000 | $459,000 | $263,000 | $76,000 |
| Stock-based compensation | $93.8M | $85.2M | $62.6M | $37.7M | $20.8M |
| Capital expenditure | $480,000 | $270,000 | $582,000 | $702,000 | $308,000 |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M | -$108.5M |
Shares outstanding 51.5M · Free float 63.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.